- Home
- GH vs ADMA Comparison
GH vs ADMA Comparison
Compare GH & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GH
- ADMA
- Stock Information
- Founded
- GH 2011
- ADMA 2004
- Country
- GH United States
- ADMA United States
- Employees
- GH N/A
- ADMA 624
- Industry
- GH Medical Specialities
- ADMA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GH Health Care
- ADMA Health Care
- Exchange
- GH Nasdaq
- ADMA Nasdaq
- Market Cap
- GH 4.3B
- ADMA 4.1B
- IPO Year
- GH 2018
- ADMA N/A
- Fundamental
- Price
- GH $31.83
- ADMA $17.40
- Analyst Decision
- GH Strong Buy
- ADMA Strong Buy
- Analyst Count
- GH 14
- ADMA 4
- Target Price
- GH $39.93
- ADMA $21.25
- AVG Volume (30 Days)
- GH 1.6M
- ADMA 2.8M
- Earning Date
- GH 11-06-2024
- ADMA 11-07-2024
- Dividend Yield
- GH N/A
- ADMA N/A
- EPS Growth
- GH N/A
- ADMA N/A
- EPS
- GH N/A
- ADMA 0.28
- Revenue
- GH $692,256,000.00
- ADMA $382,809,000.00
- Revenue This Year
- GH $32.23
- ADMA $66.84
- Revenue Next Year
- GH $16.90
- ADMA $14.72
- P/E Ratio
- GH N/A
- ADMA $62.07
- Revenue Growth
- GH 29.20
- ADMA 63.39
- 52 Week Low
- GH $15.81
- ADMA $4.16
- 52 Week High
- GH $38.53
- ADMA $23.64
- Technical
- Relative Strength Index (RSI)
- GH 45.64
- ADMA 36.96
- Support Level
- GH $34.20
- ADMA $17.32
- Resistance Level
- GH $36.24
- ADMA $18.97
- Average True Range (ATR)
- GH 1.70
- ADMA 0.75
- MACD
- GH -0.92
- ADMA -0.30
- Stochastic Oscillator
- GH 15.98
- ADMA 10.32
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
About ADMA ADMA Biologics Inc
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.